- Home
- RDIB vs ACRS Comparison
RDIB vs ACRS Comparison
Compare RDIB & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDIB
- ACRS
- Stock Information
- Founded
- RDIB 1937
- ACRS 2012
- Country
- RDIB United States
- ACRS United States
- Employees
- RDIB N/A
- ACRS N/A
- Industry
- RDIB Movies/Entertainment
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- RDIB Consumer Discretionary
- ACRS Health Care
- Exchange
- RDIB Nasdaq
- ACRS Nasdaq
- Market Cap
- RDIB 140.2M
- ACRS 132.0M
- IPO Year
- RDIB N/A
- ACRS 2015
- Fundamental
- Price
- RDIB $6.81
- ACRS $2.72
- Analyst Decision
- RDIB
- ACRS Strong Buy
- Analyst Count
- RDIB 0
- ACRS 5
- Target Price
- RDIB N/A
- ACRS $8.75
- AVG Volume (30 Days)
- RDIB 2.4K
- ACRS 1.1M
- Earning Date
- RDIB 12-31-2024
- ACRS 11-06-2024
- Dividend Yield
- RDIB N/A
- ACRS N/A
- EPS Growth
- RDIB N/A
- ACRS N/A
- EPS
- RDIB N/A
- ACRS N/A
- Revenue
- RDIB $197,270,000.00
- ACRS $27,079,000.00
- Revenue This Year
- RDIB N/A
- ACRS N/A
- Revenue Next Year
- RDIB $14.40
- ACRS N/A
- P/E Ratio
- RDIB N/A
- ACRS N/A
- Revenue Growth
- RDIB N/A
- ACRS 26.35
- 52 Week Low
- RDIB $5.89
- ACRS $0.86
- 52 Week High
- RDIB $21.34
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- RDIB 54.80
- ACRS 41.17
- Support Level
- RDIB $6.25
- ACRS $2.91
- Resistance Level
- RDIB $6.97
- ACRS $3.29
- Average True Range (ATR)
- RDIB 0.20
- ACRS 0.29
- MACD
- RDIB 0.07
- ACRS -0.18
- Stochastic Oscillator
- RDIB 83.16
- ACRS 0.75
About RDIB Reading International Inc Class B
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial, and live theater assets.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.